Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Amberen
The First People's Hospital of Lianyungang
Climacteric Syndrome
1 trial -
Ambrisentan
The First People's Hospital of Lianyungang
Pulmonary Arterial Hypertension
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Anti-HER2 CAR-T cells
The First People's Hospital of Lianyungang
HER2-positive Advanced Malignant Solid Tumors
1 trial -
AntiPlatelet therapy
The First People's Hospital of Lianyungang
Coronary Artery Disease
1 trial -
Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
The First People's Hospital of Lianyungang
Ovarian Cancer
1 trial -
Aspirin
The First People's Hospital of Lianyungang
Anterior Ischemic Optic Neuropathy
1 trial -
Atorvastatin
The First People's Hospital of Lianyungang
Contrast-induced Acute Kidney Injury
1 trial -
Atorvastatin 20 Mg Oral Tablet
The First People's Hospital of Lianyungang
Atherosclerotic Cardiovascular Disease
1 trial -
Atorvastatin Calcium 20Mg Tab
The First People's Hospital of Lianyungang
Hyperlipidemias
1 trial -
BCL regimen
The First People's Hospital of Lianyungang
Peripheral T-cell Lymphoma
1 trial -
BCMA-CART
The First People's Hospital of Lianyungang
Multiple Myeloma
1 trial -
BRL-101
The First People's Hospital of Lianyungang
Sickle Cell Disease
1 trial -
Bactoblis
The First People's Hospital of Lianyungang
Oral Disease
1 trial -
Basic treatment
The First People's Hospital of Lianyungang
Major Depressive Disorder
1 trial -
Best medical management
The First People's Hospital of Lianyungang
Stroke, Ischemic
1 trial -
Bevacizumab
The First People's Hospital of Lianyungang
Brain Glioma
1 trial -
Bifidobacterium
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
Bivalirudin
The First People's Hospital of Lianyungang
ST-segment Elevation Myocardial Infarction (STEMI)
1 trial -
Botulinum Toxin Type A Injection [Botox]
The First People's Hospital of Lianyungang
Rosacea
1 trial -
Breast MRI interpretation
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Breztri Aerosphere
The First People's Hospital of Lianyungang
Lung Cancer, Nonsmall Cell
1 trial -
Budesonide/formoterol
The First People's Hospital of Lianyungang
COPD Exacerbation
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources